Eden Radioisotopes scores funding for isotope reactor production
advertisement
Ubicación actual:
>
> This Story


Conexión o Registro to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Molecular Imaging Homepage

FDG PET better for measuring Alzheimer's cognitive function than amyloid PET (FDG) PET measures brain glucose consumption

PSMA PET/CT may beat Axumin for locating recurring prostate cancer, says study Researchers at UCLA compare imaging approaches

Progenics collabs with VA on AI research for prostate cancer treatment Apply machine learning to medical images

NNSA awards agreements to US firms for Mo-99 production Will produce with no highly-enriched uranium

ANSTO to hike nuclear medicine prices by as much as nine percent Follows Mo-99 leak

New bill calls for changing reimbursement for radiopharmaceuticals Aims for greater patient access to nuclear medicine exams

Bracco Imaging to acquire Blue Earth Diagnostics for $450 million Will gain rights over Axumin

First dual PET isotope scans performed on living organism Discussed at SNMMI 2019 Annual Meeting

Siemens showcases works in progress at SNMMI Includes TeamPlay, syngo Virtual Cockpit and a number of AI algorithms

MiE showcases cardiac PET scanner, Ancoris, at SNMMI Provides simultaneous 3D cardiac PET perfusion and CFR

Eden Radioisotopes is constructing a
reactor that will primarily produce
Mo-99

Eden Radioisotopes scores funding for isotope reactor production

por John R. Fischer , Staff Reporter
Startup Eden Radioisotopes has established an investment agreement with Yates Family company Abo Empire that will help fund the construction of a reactor for the production of medical isotopes.

The New Mexico-based nuclear structure will be less than 2 MW and used primarily to generate Molybdenum-99, the parent isotope of Technetium-99m. Its construction is expected to help curb the impact of supply shortages of the highly desirable radioisotope for molecular imaging.

Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.



“The Eden approach uses a historically well understood reactor and low-enriched uranium Mo-99 target science that has been validated to produce commercial quantities of Mo-99,” Chris Wagner, COO of Eden Radioisotopes, told HCB News. “The Eden reactor uses an all-target core that would operate 22 hours, seven days a week. This allows for Molybdenum-99 targets to be continuously irradiated and readily available for processing as needed. Other typical current medical isotope reactors may operate on a cycle of some period of time, such as 28 days, and then be down for a week of routine maintenance. During times of market shortage(s), this operational difference would allow Eden to quickly ramp up mo-99 production to fill a shortfall.”

A $4 billion-a-year global market, 40 million diagnostic molecular imaging procedures take place each year worldwide, with 80 percent requiring Technetium-99m. Of that amount, 90 percent are either cardiac or cancer-related.

Distribution of Mo-99, however, is a challenge, due to its short half-life, which prevents it from being stockpiled. In addition, only five reactors in Canada, Netherlands, South Africa, Belgium and Australia are primary producers of the isotope and often encounter numerous unplanned outages for repairs, due to their ages. This leads to supply shortages and hikes in the cost, scenarios which may become more frequent, with the Canadian reactor now offline and the 60-year-old Dutch one predicted to be at the end of its lifespan.

To keep demand stable, Eden plans to utilize exclusively licensed, patented reactor technology from Sandia National Laboratories to generate Mo-99 in large quantities. The reactor will utilize an all-target, variable-sized core of low-enriched uranium, which only requires downtime measured in hours instead of days, with the entire core of Mo-99 targets able to be processed to produce more than 10,000 Curies of Mo-99 per week.

Its size, which is similar to that of research reactors on many university campuses across the U.S., also helps reduce the costs for fuel, downtime, maintenance, personnel and large-scale operations that make large reactors, which range from 10 MW to 200 MW, not cost-effective.
  Pages: 1 - 2 >>

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment